Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Up 1.1% – Here’s What Happened

Posted by Geri Gentry on Jun 28th, 2026

Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) shares shot up 1.1% on Friday . The company traded as high as $1.00 and last traded at $0.97. 141,224 shares were traded during trading, a decline of 26% from the average session volume of 190,246 shares. The stock had previously closed at $0.9598.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Phio Pharmaceuticals has an average rating of “Hold” and an average target price of $14.00.

Check Out Our Latest Report on Phio Pharmaceuticals

Phio Pharmaceuticals Price Performance

The stock has a 50 day simple moving average of $1.11 and a two-hundred day simple moving average of $1.14. The company has a market cap of $11.27 million, a price-to-earnings ratio of -0.70 and a beta of 0.82.

Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). As a group, research analysts forecast that Phio Pharmaceuticals Corp. will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Cetera Investment Advisers boosted its holdings in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) by 26.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,500 shares of the company’s stock after buying an additional 9,000 shares during the quarter. Cetera Investment Advisers owned 0.39% of Phio Pharmaceuticals worth $45,000 as of its most recent SEC filing. Institutional investors and hedge funds own 57.31% of the company’s stock.

About Phio Pharmaceuticals

(Get Free Report)

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.